Radiation Oncology

Immunotherapy

Questions discussed in this category

Should durvalumab consolidation still be offered to Stage III NSCLC patients with PD-L1< 1%?

Do the results of the unplanned subset analysis of the PACIFIC trial showing no OS benefit in this population lean you away from consolidation?

3 Answers available

How do you prescribe a steroid taper for radiation and checkpoint inhibitor related pneumonitis?

I've seen a handful of fatal radiation pneumonitis associated with rapid steroid tapers by the non-treating physicians. How do you recommend prescribi...

1 Answer available

Would you ever consider definitive thoracic RT with concurrent immunotherapy in Stage III NSCLC?

I recently saw a patient who had been treated with concurrent pembrolizumab-RT elsewhere. Is this an acceptable practice outside the setting of a clin...

2 Answers available

Would you hold off on whole brain radiotherapy for a patient with metastatic NSCLC and multiple asymptomatic brain metastases and will be starting immunotherapy?

5 Answers available

Do you hold immunotherapy when administering lung SBRT?

One example of this scenario would be a patient receiving consolidative durvalumab after chemoRT for stage III NSCLC who develops a new peripheral lun...

3 Answers available

Is it safe to deliver SBRT with concurrent immunotherapy to head and neck sites of progressive metastatic disease?

What doses and constraints do you use?

1 Answer available

How would you approach a BRAF negative metastatic melanoma patient on immune checkpoint inhibitor therapy with enlarging, symptomatic brain lesions that had previously been treated with SRS?

If on pembrolizumab or nivolumab, when would you escalate to ipilimumab/nivolumab?

1 Answer available

How do you manage pneumonitis in patients with Stage III NSCLC receiving durvalumab?

How do you prescribe a steroid taper? If it is grade 2, would you keep them on low dose prednisone while continuing? When do you feel comfortable re-c...

2 Answers available

Do you offer consolidative thoracic radiation for oligometastatic NSCLC following upfront immunotherapy?

In patients who have a mixed response or progression and are poor candidates for other systemic agents, would you consider consolidating the chest? Wo...

2 Answers available

How do you monitor response for stage III NSCLC patients receiving consolidation immunotherapy?

CT or PET? If so, how often?

3 Answers available

Does consolidation durvalumab increase the risk of pneumonitis in Stage III NSCLC?

Rate of pneumonitis was low in the PACIFIC trial but does it mirror the real world setting? We are seeing increased pneumonitis in our practice.

2 Answers available

Do you stop consolidative durvalumab after one year as per the PACIFIC trial or continue if the patient is otherwise tolerating well?

1 Answer available

Do you routinely hold immunotherapy during whole brain radiation?

2 Answers available

Would you treat a patient with HIV or hepatitis C with an anti-PD-1 agent?

These patients have been largely excluded from these trials. What if the infection is well controlled?

3 Answers available

When giving palliative lung radiation to a patient on immune checkpoint blockade for NSCLC, do you hold immunotherapy?

If not what radiation fractionation regimen is preferred for otherwise good KPS patient?

1 Answer available

How should RT be combined with immunotherapy to generate an abscopal response?

Is there any consensus regarding the optimal RT dose, fractionation, and timing to the best abscopal response? What is the optimal metastatic site to ...

1 Answer available

Is there a role for anti PD-1/checkpoint inhibitors or other immunotherapies with radiation?

Are there any open clinical trials testing this?

1 Answer available